SCYNEXIS, Inc.

JERSEY CITY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update highlighting the completion of a Phase 1 study of SCY-770 in support of its planned Phase 2 program in Autosomal Dominant Polycystic Kidney Disease (ADPKD), the awa…

JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SCYNEXIS senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston.

JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of the intravenous (IV) formulation of SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate. SCY-247 is under development in both oral an…

JERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, announces that SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate, will be featured in an oral company pipeline presentation at IDWeek, being held October 21-24, 2026 at the Walter E. Washington Convention Center in Washington, D.C. SCY-247 is under dev…

SCYNEXIS, Inc. (NASDAQ: SCYX - Get Free Report) shares passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $4.93 and traded as high as $5.29. SCYNEXIS shares last traded at $4.84, with a volume of 162,321 shares traded. Analysts Set New Price Targets Several brokerages

• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated

Amarin (NASDAQ: AMRN - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership. Institutional and Insider Ownership 22.3% of Amarin shares are

JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, to advance the develop…

Adherex Technologies (NASDAQ: FENC - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Analyst Recommendations This is a summary of recent

JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K.

JERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Todd Minga, M.D.

Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies

SCYNEXIS, Inc. (NASDAQ: SCYX - Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $4.78 and traded as high as $5.35. SCYNEXIS shares last traded at $5.15, with a volume of 33,068 shares traded. Wall Street Analysts Forecast Growth A

JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:

JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of the Senior Director's employment with the Company, as a material induceme…